Market Overview

UPDATE: Stifel Nicolaus Raises PT on Santarus Following GI Physician Survey

Share:
Related SNTS
UPDATE: Stifel Downgrades Santarus Following SLXP Acquisition
Benzinga's Top Downgrades

In a report published Monday, Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Santarus (NASDAQ: SNTS), and raised the price target from $22.00 to $24.00.

In the report, Stifel Nicolaus noted, “With Uceris (induction of remission, active mild-moderate ulcerative colitis/UC) several months into launch, we surveyed 30 gastroenterologists (May) to gauge perception, prescribing behavior, and off-label potential. Most notably, physicians are very satisfied with Uceris, ascribing high marks on efficacy/tolerability. Prescribing comfort is driven by familiarity with budesonide (from Entecort) and MMX delivery (from Lialda). Interestingly, over half surveyed indicated comfort to prescribe Uceris off-label in microscopic colitis, Crohn's with colon involvement, and UC maintenance, indicating decent upside to peak opportunity. This confirms anecdotal reports at recent conferences. Given the solid launch trajectory and untapped growth potential, we raise our long-term Uceris estimates and increase our SNTS target price to $24.”

Santarus closed on Friday at $21.24.

Latest Ratings for SNTS

DateFirmActionFromTo
Dec 2013Stifel NicolausDowngradesBuyHold
Nov 2013Roth CapitalDowngradesBuyNeutral
Nov 2013Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for SNTS
View the Latest Analyst Ratings

Posted-In: Annabel Samimy Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (SNTS)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→